Artra Group
6029
Daiwa Cycle
5888
Asiro
7378
Business Coach
9562
D. Western Therapeutics Institute
4576
(FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | (Q1)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 3.85%573.51B | 1.24%160.94B | 1.81%150.01B | 6.75%129.7B | 6.78%132.85B | 14.24%552.24B | 7.01%158.97B | 12.03%147.35B | 15.79%121.5B | 26.44%124.42B |
Cost of revenue | 3.76%485.39B | 1.61%137.22B | 1.06%127.87B | 7.21%108.78B | 6.46%111.52B | 14.24%467.81B | 6.15%135.05B | 12.15%126.54B | 15.08%101.47B | 28.89%104.75B |
Gross profit | 4.36%88.11B | -0.84%23.72B | 6.40%22.14B | 4.45%20.92B | 8.46%21.33B | 14.22%84.43B | 12.17%23.92B | 11.28%20.81B | 19.51%20.03B | 14.80%19.67B |
Operating expense | 5.28%72.44B | 3.65%18.82B | 4.89%18.59B | 6.02%17.58B | 6.75%17.45B | 12.30%68.81B | 9.20%18.16B | 14.17%17.72B | 14.88%16.58B | 11.31%16.35B |
Operating profit | 0.33%15.67B | -14.99%4.9B | 15.04%3.55B | -3.10%3.34B | 16.84%3.88B | 23.50%15.62B | 22.69%5.76B | -2.83%3.09B | 48.18%3.45B | 35.73%3.32B |
Net non-operating interest income (expenses) | 9.56%-369M | 35.29%-66M | -2.65%-116M | 21.00%-79M | -16.13%-108M | -12.09%-408M | -3.03%-102M | -24.18%-113M | -12.36%-100M | -9.41%-93M |
Non-operating interest income | 161.40%149M | 213.04%72M | 41.67%17M | 275.00%45M | 50.00%15M | 32.56%57M | 109.09%23M | 20.00%12M | 9.09%12M | -9.09%10M |
Non-operating interest expense | 11.40%518M | 10.40%138M | 6.40%133M | 10.71%124M | 19.42%123M | 14.25%465M | 13.64%125M | 23.76%125M | 12.00%112M | 7.29%103M |
Net investment income | 7.99%338M | -40.00%15M | 20.72%134M | -28.57%20M | 13.42%169M | 10.99%313M | 66.67%25M | 5.71%111M | 1,300.00%28M | -6.88%149M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 102.92%4M | 0 | 109.52%4M | 0 | 0 | 58.86%-137M | -166.04%-35M | 88.24%-42M | -6,100.00%-60M | 0 |
Income from associates and other participating interests | -4.80%218M | 40.82%69M | -2.44%80M | -46.15%21M | -18.64%48M | -11.24%229M | -16.95%49M | -10.87%82M | 85.71%39M | -31.40%59M |
Special income (charges) | 66.97%-866M | 85.76%-388M | -1,889.47%-378M | -117.24%-5M | -203.26%-95M | -262.15%-2.62B | -3,305.00%-2.72B | 95.92%-19M | 117.26%29M | 1,020.00%92M |
Less:Other special charges | 251.61%47M | -74.65%18M | -57.89%8M | 120.69%6M | 116.30%15M | -123.66%-31M | 291.89%71M | 216.67%19M | -119.08%-29M | -1,020.00%-92M |
Less:Write off | -69.13%819M | -86.05%370M | --370M | ---1M | --80M | 255.63%2.65B | 882.59%2.65B | --0 | --0 | --0 |
Other non-operating income (expenses) | 1.44%1.27B | 31.01%414M | 1.79%285M | 11.57%270M | -27.63%296M | -12.43%1.25B | -22.74%316M | -37.50%280M | 3.86%242M | 22.46%409M |
Income before tax | 14.20%16.26B | 50.27%4.94B | 5.11%3.56B | -1.54%3.57B | 6.37%4.19B | 4.20%14.24B | -40.51%3.29B | 16.48%3.39B | 55.80%3.63B | 35.70%3.94B |
Income tax | 5.33%5.52B | -3.67%1.55B | 14.69%1.31B | 9.20%1.34B | 4.53%1.32B | 8.99%5.24B | -9.51%1.61B | -10.20%1.14B | 78.75%1.23B | 17.77%1.26B |
Net income | 19.36%10.75B | 101.72%3.4B | 0.27%2.25B | -7.04%2.23B | 7.24%2.87B | 1.61%9B | -55.14%1.68B | 37.29%2.24B | 46.10%2.4B | 46.18%2.68B |
Net income continuous operations | 19.36%10.75B | 101.84%3.4B | 0.22%2.25B | -7.04%2.23B | 7.24%2.87B | 1.60%9B | -55.18%1.68B | 37.29%2.24B | 46.19%2.4B | 46.15%2.68B |
Noncontrolling interests | 44.19%633M | 4.64%158M | 71.60%139M | 56.31%161M | 68.27%175M | 27.25%439M | 106.85%151M | -8.99%81M | 41.10%103M | -5.45%104M |
Net income attributable to the company | 18.09%10.11B | 111.37%3.24B | -2.36%2.11B | -9.93%2.07B | 4.78%2.7B | 0.56%8.56B | -58.39%1.53B | 39.87%2.16B | 46.49%2.3B | 49.42%2.57B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 18.09%10.11B | 111.37%3.24B | -2.36%2.11B | -9.93%2.07B | 4.78%2.7B | 0.56%8.56B | -58.39%1.53B | 39.87%2.16B | 46.49%2.3B | 49.42%2.57B |
Gross dividend payment | ||||||||||
Basic earnings per share | 18.09%300.93 | 111.35%96.31 | -2.41%62.78 | -9.89%61.57 | 4.78%80.27 | 0.56%254.84 | -58.39%45.57 | 39.94%64.33 | 46.38%68.33 | 49.48%76.61 |
Diluted earnings per share | 18.09%300.93 | 111.37%96.3092 | -2.39%62.78 | -9.89%61.57 | 4.78%80.27 | 0.56%254.84 | -58.39%45.5642 | 39.91%64.3147 | 46.42%68.33 | 49.48%76.61 |
Dividend per share | 24.68%48 | 30.00%26 | 0 | 18.92%22 | 0 | 6.94%38.5 | 8.11%20 | 0 | 5.71%18.5 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |